A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with Lung Cancer
Kunihiko Kobayashi(Saitama International Medical Center), Kiyokazu Yoshida(Saitama Cancer Center), Hiroshi Sakai(Hiroshima University), Yukio Noguchi(Saitama Cancer Center), Isao Gotoh(Saitama Cancer Center), Hideto Ogasawara(Saitama Cancer Center), Fumikazu Takeda(Saitama Cancer Center), Shuichi Yoneda(Saitama Cancer Center), Satoshi Teramukai(Kyoto University Hospital)
Cited by 255
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
|JNCI Journal of the National Cancer Institute|1993|15.9k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy
|New England Journal of Medicine|2018|551
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
|Journal of Clinical Oncology|2019|483